Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris

NCT05131373 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Acne Vulgaris
Acne

Interventions

DRUG: ORG101 - Experimental 1
DRUG: ORG101PL - Placebo 1

Sponsor

Sanofi Pasteur, a Sanofi Company